ArticleJournal of diabetes research2026
Mechanistic Elucidation of Yiqi Yangyin Qingre Decoction in Diabetic Nephropathy Therapy via Network Pharmacology and In Vivo Validation.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic Elucidation of Yiqi Yangyin Qingre Decoction in Diabetic Nephropathy Therapy via Network Pharmacology and In Vivo Validation.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundDiabetic nephropathy (DN) is a serious microvascular complication of diabetes that urgently requires effective treatments with low toxicity. The traditional Chinese medicine formula Yiqi Yangyin Qingre decoction (YQYYQR) has demonstrated potential in alleviating DN, yet its pharmacological mechanism remains unclear.
methodsUPLC-MS/MS combined with network pharmacology was utilized to qualitatively analyze YQYYQR's bioactive components and predict therapeutic targets. Integrating public databases and GEO-derived DN-related genes, core targets were identified via intersection and subjected to pathway enrichment. Molecular docking validated key component-core target interactions, with in vivo DN mouse experiments and transcriptome sequencing performed for verification.
resultsThis study identified 376 bioactive components from YQYYQR, corresponding to 1284 potential therapeutic targets. Cross-analysis between these targets and DN-related genes yielded 57 overlapping targets, among which GSK3β and NFKB1 were screened as core hub genes. Network pharmacology and transcriptomic pathway enrichment analyses indicated that the mechanism of YQYYQR in intervening DN involves biological processes such as autophagy and inflammatory response. In vivo, YQYYQR significantly improved mouse proteinuria and renal function and alleviated pathological kidney damage. Mechanistically, YQYYQR enhanced the inhibitory phosphorylation of GSK3β at Ser9, thereby facilitating TFEB nuclear translocation and activating the autophagy-lysosomal pathway. Simultaneously, it suppresses the NLRP3/ASC/caspase-1/GSDMD-N-mediated pyroptosis pathway, ultimately reducing renal inflammation.
conclusionYQYYQR exerts a protective effect against DN progression by targeting core genes including GSK3β, regulating the GSK3β-TFEB axis to restore autophagic flux via the autophagy-lysosomal pathway, and inhibiting NLRP3-mediated pyroptosis to mitigate excessive renal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.